Tag: LimFlow

FDA Approves LimFlow System in Patients With Chronic Limb-Threatening Ischemia and No Suitable Endovascular or Surgical Revascularization Options

PARIS & SAN JOSE, Calif.–(BUSINESS WIRE)–LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), announced today that the U.S. Food and Drug Administration (FDA) has approved the LimFlow System to help people with […]

Landmark New England Journal of Medicine Publication Reports Positive Results From PROMISE II Pivotal Trial Showing that LimFlow System Saves Most Patients with End-stage Peripheral Artery Disease From Major Amputation

PROMISE II Trial Met Primary Endpoint Therapy Demonstrates 76% Limb Salvage in Patients with Chronic Limb-Threatening Ischemia Who Otherwise Faced Amputation PARIS–(BUSINESS WIRE)–LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), announced today […]

Limflow Appoints Mike Mathias as Vice President, Commercial Operations

PARIS–(BUSINESS WIRE)–LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), today announced the appointment of Mike Mathias as Vice President of Commercial Operations. Mr. Mathias has spent his 30-year career successfully leading sales organizations […]

LimFlow Appoints Jenny Gaffney as Vice President, Health Economics and Reimbursement

PARIS–(BUSINESS WIRE)–LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), today announced the appointment of Jenny Gaffney as Vice President, Health Economics and Reimbursement. Ms. Gaffney brings to LimFlow over 15 years of rich […]

LimFlow Raises $40 Million (€36 Million) in Series D Financing

Funds to Support Completion of Clinical Program Through Commercialization of Novel Device Designed to Prevent Amputations in Patients with Chronic Limb-Threatening Ischemia PARIS–(BUSINESS WIRE)–LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), today announced […]

Late-breaking Data From PROMISE I Study On LimFlow System Confirm Excellent Sustained Outcomes In Patients With No-option Chronic Limb-threatening Ischemia

Limb salvage in 77 percent of patients at 2 years with “no-option” for revascularization via traditional techniques 24-Month Results Presented Wednesday at VIVA 2021 Conference SAN JOSE, Calif. and LAS VEGAS, Oct. 7, 2021 /PRNewswire/ — LimFlow SA, the pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a […]

LimFlow System Demonstrates Excellent Sustained Amputation-free Survival and Wound Healing at One Year in PROMISE I U.S. Study

Twelve-Month Results Presented Today in Late-Breaking Trials Session at Vascular Interventional Advances (VIVA) Conference PARIS–(BUSINESS WIRE)–LimFlow SA, the pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), today announced the presentation of 12-month data from the […]

Publication of Two-Year Outcomes for LimFlow System Shows Excellent Amputation-Free Survival and Wound Healing in Patients With No-Option Chronic Limb-Threatening Ischemia

Multicenter, International ALPS Registry Outcomes Just Published in Journal of Endovascular Therapy PARIS–(BUSINESS WIRE)–LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease (PAD), today announced publication of positive two-year data from the ALPS Registry of […]

CORRECTING and REPLACING First Patient Enrolled in PROMISE II U.S. Pivotal Study of LimFlow System to Treat Chronic Limb-threatening Ischemia

Clinical Study to Evaluate Device’s Ability to Prevent Amputation and Promote Wound Healing in Patients with No Other Options CORRECTION…by LimFlow SA PARIS–(BUSINESS WIRE)–First paragraph, last sentence should read: The successful first case was performed by Mark Archie, MD, principal investigator for the PROMISE II trial at Harbor-UCLA Medical Center, […]